Clinical trials located in

Limoges

Limoges city is located in France. Currently, 20 clinical trials are being conducted in this city.

Limoges, located in southwest-central France, is renowned for its medieval and Renaissance enamels on copper, 19th-century porcelain, and oak barrels used in Cognac production. Established by the Romans around 10 BCE, the city boasts a rich history evident in its Gothic Cathédrale Saint-Étienne and the Crypt of Saint-Martial from the 10th century. Limoges played a pivotal role in the French Resistance during World War II. Its unique landscape is part of the Limousin region, known for its lush forests and the Vienne River.

  • CT-EU-00121560

    Study of the safety and effectiveness of GLSI-100 in patients with HER2-positive breast cancer

    The study concerns the treatment of patients with HER2/neu-positive breast cancer. Treatment will include GLSI-100 immunotherapy and comparison to placebo. GLSI-100 consists of GP2 peptide and GM-CSF, protein substances that are designed to strengthen the body’s immune response, i.e. natural protection against diseases.

    The aim of this study is to determine how effective and safe GLSI-100 therapy is compared to placebo in preventing breast cancer recurrence after standard treatment. The study is aimed at people at high risk of disease recurrence who have completed both preoperative and postoperative therapy based on trastuzumab, a drug used to treat breast cancer.

    The study will assess invasive breast cancer-free survival (i.e. the time from the first dose of the drug to the moment of disease recurrence or death from any cause), invasive disease-free survival (i.e. the time from the first dose of the drug to the moment of any disease recurrence or new cancer), remote disease (i.e. time until disease recurrence in a place other than the breast or death).

    The study also includes an assessment of the participants’ quality of life both at the beginning and over the next 36 months, as well as an analysis of the body’s immune response to treatment.

  • Isatuximab Plus Pomalidomide and Dexamethasone for AL Amyloidosis

    This clinical trial is focused on patients with AL Amyloidosis who have not achieved a very good partial response or better following previous therapies. The trial investigates the efficacy of combining Isatuximab, Pomalidomide, and Dexamethasone. The aim is to see if this drug combination can significantly reduce the levels of misfolded proteins in the blood, which are characteristic of this disease, thereby improving the condition and potentially prolonging life. This study seeks to offer a new potential treatment option for those who have limited responses to existing therapies.

    • Isatuximab
  • Study of a new drug for moderate to severe Rotator Cuff Tendinopathy

    The clinical trial examines the use of secukinumab, a drug, for treating moderate to severe rotator cuff tendinopathy—a shoulder condition characterized by pain and limited movement. The study explores whether secukinumab can improve symptoms and physical function compared to a placebo. Participants will receive either the drug or placebo in addition to standard care, under a randomized, double-blind, and placebo-controlled setup, to ensure the results are unbiased.

    • placebo
    • Secukinumab
  • Exploring ELVN-001 in a trial for chronic myeloid leukemia safety and efficacy

    The study being described is a Phase 1 clinical trial of a drug named ELVN-001, which is being tested for the treatment of chronic myeloid leukemia (CML). This trial aims to evaluate the safety and effectiveness of ELVN-001, particularly its ability to be tolerated by patients and its impact on the disease. The study is designed to first determine the most suitable dose of ELVN-001 and then observe its effects on patients who have either relapsed from or are intolerant to standard treatments. The trial will involve administering the drug and monitoring patients for any reactions or improvements in their condition.

    • ELVN-001
  • Combining Azacitidine and Venetoclax for Higher-Risk Chronic Myelomonocytic Leukemia

    The AVENHIR study is an open-label clinical trial for patients with higher-risk chronic myelomonocytic leukemia, a type of blood cancer. This study will evaluate the effectiveness and safety of combining two drugs: Azacitidine and Venetoclax (also known as ABT-199). Azacitidine is a chemotherapy drug, while Venetoclax is a targeted therapy that works by blocking a specific protein in cancer cells.

    The main goals of the study are to determine the overall response rate to this drug combination, which means how many patients achieve complete remission, partial remission, or clinical benefit. The study will also closely monitor safety and any potential dose-limiting side effects during the first two treatment cycles.

    To be eligible for this study, patients must be newly diagnosed with higher-risk chronic myelomonocytic leukemia and have not received any prior treatment with hypomethylating agents like Azacitidine.

    • Venetoclax
  • Exploring a new treatment combination for rheumatoid arthritis: baricitinib plus anti-TNF

    This clinical trial is focused on finding a more effective treatment for people with Rheumatoid Arthritis (RA) who haven’t responded well to previous therapies. The study is comparing two different approaches: one group will receive a combination of baricitinib treatment and an anti-TNF therapy (adalimumab), while the other group will receive baricitinib along with a placebo. The main goal is to see which group shows a greater improvement in their RA symptoms, specifically looking for a 50% improvement in symptoms, known as an ACR 50 response, after 24 weeks from the start of the treatment.

    Baricitinib is a medication that targets certain pathways in the body’s immune system to reduce inflammation and pain in RA. Anti-TNF therapy, like adalimumab, works by blocking the action of a protein in the body that causes inflammation. By combining these two treatments, researchers hope to see a more significant improvement in RA symptoms than with baricitinib alone.

    The trial is important because it aims to provide a new option for patients with RA who have not found relief with current treatments. It’s designed to test the safety and effectiveness of using these two different types of medications together.

    • placebo
    • Adalimumab
    • Baricitinib
  • CT-EU-00083874

    Study to find the best way to administer pegaspargase in children with acute lymphoblastic leukemia

    This is a study to investigate treatment strategies for children and adolescents diagnosed with acute lymphoblastic leukemia (ALL). The study focuses on evaluating the efficacy of a drug called pegaspargase. The drug works by depriving tumor cells of essential nutrients, contributing to its potential efficacy against ALL in pediatric patients. The study aims to determine the optimal way to administer pegaspargase, comparing a single high dose with two lower doses, with additional doses later in treatment. For those at highest risk, a more intensive treatment plan is being investigated. This includes two larger initial doses, followed by additional doses later in treatment. The study is evaluating factors such as potential serious side effects and overall treatment efficacy.

    • pegaspargase
  • Venetoclax in recurrence of blood cancer after previous stem cell transplantation

    This study aims to investigate the effectiveness and safety of a novel treatment approach, combining the drugs venetoclax and azacitidine, along with donor lymphocyte infusion (DLI) in patients experiencing a relapse of one of two of blood-related disorders: myelodysplastic syndrome (condition where blood cells do not develop properly) or acute myeloid leukemia (bone marrow cells become abnormal and begin to accumulate in excess), following stem cell transplantation. The study involves a group of patients for whom standard treatments have not yielded satisfactory results. The objective is to understand whether the combination of new drugs and donor lymphocyte infusion can effectively control these blood disorders, especially after stem cell transplantation. Researchers are monitoring side effects, assessing disease progression, and determining the safety of the procedure. The results may provide valuable insights into effective therapeutic strategies for these challenging blood-related disorders.
    • azacitidine
    • venetoclax
  • Testing nivolumab alone and with Ipilimumab for advanced bowel cancer

    This study is about testing different treatments for a type of advanced bowel cancer called Metastatic Colorectal Cancer, which offers certain genetic features (called MSI-H or dMMR). The study aims to compare the efficacy of treatment approaches for cancer. One involves the use of the drug Nivolumab alone, and the other combines Nivolumab with another drug called Ipilimumab. These approaches will be compared against the benefits of conventional chemotherapy, as determined by the treating physician. The study will evaluate factors such as the extent of cancer shrinkage and the duration of growth inhibition.

    • Nivolumab
    • Ipilimumab
    • Fluorouracil
    • Leucovorin
    • Bevacizumab
    • Cetuximab
    • Irinotecan
    • Oxaliplatin
  • Study of lacutamab in T-cell lymphoma

    This trial involves a medication called lacutamab, which will be given to patients who have a type of blood cancer known as peripheral T-cell lymphoma, and their disease has either come back after previous treatment or didn’t respond at all. Some patients in the study will receive lacutamab in combination with a common chemotherapy drugs gemcitabine and oxaliplatine, while others will get only gemcitabine and oxaliplatine. A key aim of this study is to find out if lacutamab is both safe and effective. The study is designed not to compare the two treatments directly, but to check our assumptions for deciding the number of people for the trial. The number of participants getting lacutamab is bigger.

    • Lacutamab
    • Oxaliplatine
    • Gemcitabine
  • Comparing favezelimab/pembrolizumab combo with standard chemotherapy for Hodgkin lymphoma

    This study is investigating a treatment for PD-(L)1-refractory, relapsed, or refractory classical Hodgkin lymphoma, a type of blood cancer. Researchers are evaluating a new drug combination known as MK-4280A (favezelimab/pembrolizumab) alongside standard drugs typically used for this condition (bendamustine or gemcitabine). The aim is to determine if MK-4280A is superior to the standard drugs in extending patients’ lifespan and slowing down disease progression. Additionally, scientists will assess the safety and tolerability of MK-4280A during the study, noting any potential side effects of the drug.

    • Favezelimab
    • Pembrolizumab
    • Bendamustine
    • Gemcitabine
  • Evaluating effects of pembrolizumab with chemotherapy and radiation for esophageal cancer

    This trial explores the impact of a drug called pembrolizumab on patients with a specific kind of cancer, Esophageal Carcinoma. It compares two treatments. Some patients will receive the standard treatment (chemotherapy and radiation), plus a placebo. Others will receive the standard treatment (chemotherapy and radiation) plus Pembrolizumab. The reason for doing it is to see if Pembrolizumab, when added to normal treatment, can help patients live without their cancer getting worse, or live longer overall. During the trial, patients will either be given pembrolizumab or placebo, as well as one of two chemotherapy combinations and radiation treatment, for about a year.

    • Pembrolizumab
    • levoleucovorin
    • leucovorin
    • 5-Fluorouracil
    • Cisplatin
    • Oxaliplatin
  • Study on intensified chemotherapy for Resectable Soft-tissue Sarcomas treatment

    This study aims to investigate whether administering additional chemotherapy before surgery can benefit individuals with soft-tissue sarcoma, a specific type of cancer. Currently, the standard treatment involves three doses of chemotherapy before surgery, sometimes followed by radiotherapy after surgery. In this study, some participants will follow this standard treatment plan, while others will receive an intensified regimen involving six doses of chemotherapy before surgery instead of three. Researchers will observe and compare outcomes such as the time it takes for the cancer to spread or worsen, overall survival rates, the extent of tumor shrinkage with the additional chemotherapy, and any potential side effects associated with the treatment.

    • Ifosfamide
    • Doxorubicin
    • Dacarbazine
  • Study of the effect of a new drug on renal disease with proteinuria

    This study focuses on the investigation of a new drug called Inaxaplin (VX-147), which is being tested in people with apolipoprotein L1 (APOL1)-dependent proteinuria kidney disease. The study took a comparative approach, with one group receiving the actual drug and the other receiving a placebo. The main objectives include assessing the effectiveness of Inaxaplin and ensuring its safety profile for consumption. The study involves assessing the physiological processing of the drug in the body, and the study population includes both adults and children.

    • Inaxaplin/VX-147
  • Testing ADT with or without darolutamide in prostate cancer patients

    This study is about testing how well two different kinds of prostate cancer treatment work. One treatment is called ADT (Androgen deprivation therapy) and the other is called darolutamide. In total, around 300 men who have just been diagnosed with prostate cancer will take part. The people in the study will be split into two groups. Half of the people will have the ADT treatment with placebo, while the other half will have both the ADT and darolutamide treatment. This will help the researchers understand whether adding darolutamide makes the ADT treatment work better. To check how well the treatment is working, the researchers will be using different methods.

    • Androgen deprivation therapy
    • Darolutamide
  • Testing Milvexian’s effectiveness in preventing repeat strokes

    This research trial, called LIBREXIA-STROKE, will test a medication called Milvexian on those who have recently had a stroke or a high-risk ‘mini-stroke’. In its 3rd testing phase, the study will involve a system where the patients won’t know whether they are receiving the actual drug or a substitute with no effect, referred to as a ‘placebo’, to maintain fairness. Milvexian is a medication that can potentially reduce the risk of having another stroke, and this trial aims to observe how effective it is in doing so. The trial will look at when the first stroke happens after starting the trial, if other major heart or limb diseases occur, or if strokes occur in the first 90 days.

    • Milvexian
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • A study of lanifibranor treatment in adults with nonalcoholic fatty liver disease

    This study is a two-part trial looking at how well a drug called Lanifibranor works for adults suffering from liver diseases known as NASH and fibrosis stages F2 and F3. In the first part of the trial, the researchers will compare the effects of Lanifibranor with a placebo, which is a substance with no medical effect. The researchers will be looking at how much the drug can improve the health of the liver. The second part of the study will continue the use of Lanifibranor to see if there are any long-term safety issues. Apart from studying the drug’s effectiveness in resolving NASH and reducing live fibrosis, the trial will also be observing how it affects other aspects of liver health, diabetes, blood sugar and fat levels, liver stiffness and patients’ quality of life.

    • Lanifibranor
  • Examining combination treatment for Myelofibrosis

    This study is about testing a new combination of drugs known as KRT-232 (Navtemadlin) and TL-895 in patients with a blood disorder called Myelofibrosis. Doctors want to see how well this combination can work for patients who have tried other treatments without success, or those who can’t tolerate another medicine called JAK inhibitor. The first two groups will go through a process of adjusting doses to find the most tolerable and effective amount of medicine. The third group will be a larger set of patients, and this part of the trial will only continue if the treatment shows enough promise in the early stages. One of the ways to measure success is through a noticeable reduction in spleen size, measured by scans at 24 weeks. Doctors will also assess the patients’ symptoms using a special form.

    • Navtemadlin/KRT-232
    • TL-895- new potential medication for hematologic malignancies

See more clinical trials in other cities in France:

.